Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study

Targeted Oncology
Hiroki IshiharaKazunari Tanabe

Abstract

Investigations on rapid disease progression in patients with urologic malignancies treated with immune checkpoint inhibitors are currently lacking. The objective of this study was to assess cases of rapid disease progression/immediate development of progressive disease (immediate PD) in patients with pretreated metastatic renal cell carcinoma (mRCC) treated with nivolumab. Forty patients were retrospectively evaluated. Immediate PD within the initial two cycles of nivolumab therapy was clinically or objectively diagnosed. Clinical diagnosis was defined as an acceleration of symptoms directly caused by tumor growth or systematic worsening of the general condition, such as cachexia. Objective diagnosis was based on imaging evaluation using the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Seven patients (17.5%) developed immediate PD. For these patients, the median time from the initiation of nivolumab treatment to PD was 14 days; all seven patients subsequently died from the cancer. Progression-free survival (0.66 vs. 10.5 months; p < 0.0001) and overall survival (1.41 months vs. not reached; p < 0.0001) were significantly shorter in patients with immediate PD than in those without immediate PD. ...Continue Reading

References

Jan 7, 2004·Nature Reviews. Cancer·Jeffrey W Pollard
Jan 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jedd D WolchokF Stephen Hodi
Apr 21, 2010·Cancer Metastasis Reviews·David G DeNardoLisa M Coussens
Aug 6, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Pei-Yi LinTyler J Curiel
Aug 23, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jamie E ChaftGregory J Riely
Mar 23, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Christoph SeidelViktor Grünwald
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Apr 29, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G MansonR Houot
Aug 23, 2016·Nature Reviews. Immunology·Sabra L Klein, Katie L Flanagan
Oct 30, 2016·Science·Debattama R SenW Nicholas Haining
Nov 9, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stéphane ChampiatCharles Ferté
Nov 22, 2016·The Lancet Oncology·Vicki Brower
Jan 20, 2017·Nature·Daniel S Chen, Ira Mellman
Mar 30, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shumei KatoRazelle Kurzrock
Apr 19, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Saâda-BouzidC Le Tourneau
Apr 19, 2017·Japanese Journal of Clinical Oncology·Yoshihiko TomitaSeiichiro Ozono
Jun 10, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·Robert J MotzerRashmi Kumar
Nov 16, 2017·Japanese Journal of Clinical Oncology·Hiroki IshiharaKazunari Tanabe
Nov 29, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M TazdaitC Caramella
Feb 15, 2018·Targeted Oncology·Jeffrey M ClarkeApril K S Salama
Mar 22, 2018·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 214 Investigators
May 21, 2018·The Lancet Oncology·Fabio ConfortiAron Goldhirsch

❮ Previous
Next ❯

Citations

Jun 9, 2021·International Journal of Clinical Oncology·Kimiharu TakamatsuMototsugu Oya

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.